171 related articles for article (PubMed ID: 24793535)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.
Liu Y; Yang C; Li Z; Zhou J; Lv Y; Zhang Y; Zeng F; Shi S
Clin Ther; 2014 Jun; 36(6):940-52. PubMed ID: 24793535
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.
Liu Y; Shi S; Wu J; Li Z; Zhou X; Zeng F
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):154-61. PubMed ID: 21771277
[TBL] [Abstract][Full Text] [Related]
3. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study.
Takács I; Jókai E; Kováts DE; Aradi I
Osteoporos Int; 2019 Mar; 30(3):675-683. PubMed ID: 30357438
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
Sturmer A; Mehta N; Giacchi J; Cagatay T; Tavakkol R; Mitta S; Fitzpatrick L; Wald J; Trang J; Stern W
Clin Pharmacokinet; 2013 Nov; 52(11):995-1004. PubMed ID: 23719683
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers.
Chu NN; Li XN; Chen WL; Xu HR
Pharmazie; 2007 Nov; 62(11):869-71. PubMed ID: 18065105
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
9. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.
Hämmerle SP; Mindeholm L; Launonen A; Kiese B; Loeffler R; Harfst E; Azria M; Arnold M; John MR
Bone; 2012 Apr; 50(4):965-73. PubMed ID: 22289659
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.
Satterwhite J; Heathman M; Miller PD; Marín F; Glass EV; Dobnig H
Calcif Tissue Int; 2010 Dec; 87(6):485-92. PubMed ID: 20953593
[TBL] [Abstract][Full Text] [Related]
12. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
Möricke R; Rettig K; Bethke TD
Clin Drug Investig; 2011; 31(2):87-99. PubMed ID: 21155613
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties and safety profile of histamine dihydrochloride injection in Chinese healthy volunteers: a phase I, single-center, open-label, randomized study.
Li J; Huang X; Wang Q; Jing S; Jiang H; Wei Z; Zang Y; Liu Y; Zhao L; Fang Y; Feng W
Clin Ther; 2015 Oct; 37(10):2352-64. PubMed ID: 26276501
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study.
Liu H; Wang H; Liu T; Jiang J; Chen X; Gao F; Hu P
Clin Ther; 2016 Feb; 38(2):348-57. PubMed ID: 26804640
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.
Hu CY; Liu YM; Liu Y; Chen Q; Wang W; Wu K; Dong J; Li J; Jia JY; Lu C; Sun SX; Yu C; Li X
Clin Ther; 2013 Dec; 35(12):1884-9. PubMed ID: 24148552
[TBL] [Abstract][Full Text] [Related]
19. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
Zhang L; Li L; Yang M; Xu K; Boden G; Yang G
Osteoporos Int; 2013 Mar; 24(3):1107-12. PubMed ID: 22419369
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
